Cellestia is a clinical-stage biopharma company targeting cancer at a level of gene transcription. The clinical candidate of Cellestia is CB-103, a novel, first-in-class oral pan-NOTCH inhibitor indicated for treatment of patients with NOTCH-driven leukemias, lymphomas and solid tumors. CB-103 is the first drug to selectively target this pathway at the level of the oncogenic transcription factor. Cellestia holds a worldwide exclusive license on the intellectual property rights for CB-103 and related series of analogues, for development and commercialization. The company pursues an integrated approach combining drug and personalized medicine development for patient selection.
